Pardoprunox

DB12061InvestigationalSmall molecule

Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease. Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with...

Mechanism: Pardoprunox binds to dopamine D(2), D(3), and D(4) receptors and 5-HT(1) (A) receptors and is a partial agonist at dopamine D(2) and D(3) receptors and a full agonist at serotonin 5-HT(1) (A) receptors. Pardoprunox combines high potency partial agonism at dopamine D(2) and D(3) receptors with full efficacy low potency serotonin 5-HT(1) (A) receptor agonism and is worthy of profiling in in vivo models of Parkinson's disease.
Curator reviewed
Formula / weight: C₁₂H₁₅N₃O₂ · 233.271 g/mol (avg)
Code names: DU-126891 · SLV-308

Resolves to

Compound

UNII5R72CHP32SCAS269718-84-5ChEMBLCHEMBL2103832PubChem6918525

Structure

InChIKeyYVPUUUDAZYFFQT-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=C2OC(=O)NC2=CC=C1

Targets

P08908HTR1AP14416DRD2P35462DRD3P21917DRD4

What you can answer from here — as of September 21, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pardoprunox, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account